BTIG Expects More Visibility for Cidara Therapeutics' (CDTX) CD101 Soon; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Wedbush Reiterates Outperform on Cidara Therapeutics (CDTX) Following 2Q
August 16, 2016 8:21 AM EDTWedbush reiterated an Outperform rating and $22.00 price target on Cidara Therapeutics (NASDAQ: CDTX) following the company's 2Q. CDTX reported a net loss of ($11.9M) or ($0.85)/share, below the consensus of ($0.76), on higher than expected R&D costs.
Analyst David Nierengarten commented, "With CD101... More
Needham & Company Reiterates Buy on Cidara Therapeutics (CDTX) Following 2Q Report
August 15, 2016 8:19 AM EDTNeedham & Company reiterated a Buy rating and $20.00 price target on Cidara Therapeutics (NASDAQ: CDTX) following the release of company's 2Q16 financial results and management updates. The Phase 2 non-inferiority STRIVE trial of IV CD101 in Candidemia (NCT02734862) is expected to enroll 90 patients, randomized 1:1:1 to standard... More
